



Microbial Extracellular L-asparaginase: An Enzyme of Therapeutic Interest

Biswaprakash Pradhan ¹, Sashi K. Dash ²,
Chandi C. Rath ³, Sweety Patel ⁴ and Sabuj Sahoo ^{*1}

¹Pharmaceutical Biotechnology Division, University Department of Pharmaceutical Sciences, Utkal University, Vani Vihar, Bhubaneswar, Odisha -751 004, India

²Department of Seed Technology, Orissa University of Agriculture and Technology, Bhubaneswar, Odisha -751 003, India

³Deputy Director (Technical), Biotechnology, Govt. of Odisha, Bhubaneswar-751001, India

⁴State Drugs Testing and Research Laboratory, Directorate of Drugs Control, Bhubaneswar, Odisha, India

Received 17 October 2014; accepted in revised form 15 November 2014

Abstract: This review article encompasses detailed information pertaining to microbial extracellular L-asparaginase, the introductory remarks on current status and future perspective of enzymes in general and overview of L-asparaginase in specific, underlying mechanism of action, therapeutic applications, microbial sources, effect of fermentation process parameters on its production, methods for purification, molecular weight and properties, biochemical aspects, assay methods side effects, therapeutic importance and scope of research. Effort has been made for inclusion of updated information and impact of newer parameters including fermentation processes, different methods for purification, properties and biochemical aspects of microbial extracellular L-asparaginase. L-asparaginase is still one of the most widely studied therapeutic enzymes by researchers and scientists worldwide.

Key Words: L-asparaginase, Acute Lymphoblastic Leukemia (ALL), Enzymatic Assay, Therapeutic Application.

Introduction

Biotechnology is gaining rapid importance as it offers several applications and advantages over conventional technologies. Enzymes are considered as the 'third wave' of biotechnology following the pharmaceutical and agricultural waves ⁵⁶.

The global market for industrial enzymes is estimated at \$3.3 billion in 2010 and expected to reach \$4.4 billion by 2015. Technical enzymes are valued at just over \$1 billion in 2010, will increase at a 6.6 % compound annual growth rate to reach

\$1.5 billion in 2015. The highest sales of technical enzymes occurred in the leather industries followed by the bioethanol, food and beverage industries ⁶⁶.

The biotech industry in India registered only 2 % of global biotech markets. But due to newer applications in food and feed, detergent and textile processing, agriculture, dairy, leather, paper, healthcare, diagnostics and environment, utilization of renewable resources for synergising the efficacy and efficiency of industrial processes, investment opportunities and monitoring of

*Corresponding author (Sabuj Sahoo)
E-mail: < sabujbiotech@rediffmail.com >

environmental degradation delivers a more bio-friendly cum bio-based economy⁵⁵, the global viability, scope and existence is tremendously improved.

During the fiscal year 2010-11 the Indian biotech sector grew at 21.5 % to reach Rs 17,400 crores in revenues. The biopharma segment continues to maintain dominance followed by the bioindustrial, bioagricultural and bioinformatics⁶⁶.

Current status of L-asparaginase

L-asparaginase (L-asparagine aminohydrolase, E.C.3.5.1.1) exclusively present in guinea pig serum was proposed to be responsible for tumouricidal effects³. The enzyme L-asparaginase is enlisted under the World Health Organization's List of Essential Medicines, registered immense therapeutic importance as an anti-neoplastic drug used in acute lymphoblastic leukemia and lymphosarcoma chemotherapy³⁸. The growth of a cell line derived from Walker carcinosarcoma was shown to be dependent on L-asparagine⁶⁵. L-asparaginase purified from guinea pig serum was a tumouricidal agent¹¹ against implanted 6C3HED cells (serum from newborn guinea pigs lacking L-asparaginase was devoid of antitumour activity). It turned out that L-asparaginase is not an anticancer drug in general but is effective against certain types of tumours and it has become an essential component of chemotherapy strategies. Using salt precipitation, starch block electro-phoresis and DEAE-cellulose column chromatography two isoforms of L-asparaginase were partially purified¹⁰⁵ and only one isoform had antilymphoma activity *in vivo*.

L-asparaginase is the first identified enzyme with antitumour activity in human beings. L-asparaginases are enlisted under cytotoxic and adjuvant medicines on WHO model list of essential medicine. It is an enzyme and drug of choice for acute lymphoblastic leukemia in children used in combination therapy⁸⁵. L-asparaginase treatment for acute lymphoblastic leukemia is a major breakthrough in modern oncology as it induces complete remissions in over 90 % children within four weeks²⁸. Since 1922, L-asparaginase has been considered as a therapeutic agent against malignant tumours¹⁷. The presence of L-asparaginase deprives tumor cells of an important

growth factor and they fail to survive⁴³. This fact suggested the development of this enzyme as a potent antitumour or antileukemic drug⁸⁰. Elspar, Oncaspar, Erwinase Kidrolase, Colaspase and Crasnitin²⁴ are the brand names of L-asparaginase.

Mechanism of action and therapeutic applications of L-asparaginase

The FDA has approved L-asparaginase for the effective treatment of acute lymphoblastic leukemia and lymphosarcoma. L-asparaginase catalyzes the hydrolysis of L-asparagine into L-aspartic acid and ammonia. L-asparagine is a major requirement by the cells for the production of protein. It can be produced within the cell by an enzyme called asparagine synthetase or can be absorbed from the outside (consumed in the diet, absorbed into the body and made available to the body's cells). Tumor cells, more specifically lymphatic tumor cells, require huge amounts of asparagine to keep up with their rapid malignant growth¹⁰⁰. Thus, the asparagine from the diet as well as what can be made by themselves (which is limited) is utilized by them to satisfy their large asparagine demand. Therefore L-asparagine is an essential amino acid for the growth of tumor cells, whereas the growth of normal cells is not dependent on its requirement as it can be synthesized in amounts sufficient for their metabolic needs with their own enzyme L-asparagine synthetase.

L-asparaginase also plays a very critical role in the biosynthesis of the aspartic family of amino acids. *Corynebacteria* producing amino acids are of great industrial interest as they excrete large amounts of various amino acids⁵⁷. Lysine, threonine and methionine are commercially important amino acids produced by *C. glutamicum*, are derived from aspartic acid, which, under normal physiological conditions, might be limiting for lysine and/or threonine biosynthesis. Apart from Krebs's cycle (using glutamic acid as amino acid donor), aspartic acid is formed from asparagine by the action of asparaginase. L-asparagine was produced constitutively and its role may be that of an overflow enzyme, converting excess asparagine into aspartic acid, the direct precursor of lysine and threonine. A very active L-asparaginase was found in *C. glutamicum*

under lysine producing fermentation conditions⁵⁸. L-asparaginase enzyme is useful against Acute Lymphoblastic Leukemia (mainly in children), Reticlesarcoma, Hodgkin disease, Acute Myelocytic Leukemia, Acute myelomonocytic Leukemia, Chronic Lymphocytic Leukemia, Lymphosarcoma and Melanosarcoma^{14,32}. The enzyme inhibited the growth of the two human cell lines including hepatocellular carcinoma (Hep-G2) and colon carcinoma (Hct-116) with IC50 value of 8.38 μ g/ml and 4.67 μ g/ml, respectively²³.

It is also used for the treatment of pancreatic carcinoma¹⁰⁷. Treatment with L-asparaginase, polyphenoloxidase and low frequency laser decreased adhesion of uro-pathogenic *Escherichia coli* to human erythrocytes⁴⁹. L-asparaginase like glutaminase and urease also plays an important role in the biogeochemical cycling of carbon and nitrogen in natural waters and sediments⁷⁶. L-asparaginase is a model enzyme for the development of new drug delivery system⁹³, L-asparagine biosensor for leukemia¹⁰⁰. L-asparaginase production by using microbial systems has attracted considerable attention, owing to the cost-effective and eco-friendly nature⁹⁰. For all clinical and non clinical uses, L-asparaginase has to be produced in larger quantities.

It is also used in food industry for the production of acrylamide (a potent carcinogen and a neurotoxic compound) free starchy fry food⁶⁹. Preventase (DSM) and Acrylaway (Novozyme) produced from *Aspergillus niger* and *A. oryzae* respectively are commercially available L-asparaginase currently used in food industry⁴⁸.

L-asparaginase produced extracellularly is advantageous and preferred over intracellular type because of higher accumulation of protein, easy extraction and downstream processing^{2,52}. The extracellular compartment in bacteria is protease deficient and the liberated protein exported to the medium is mostly soluble, biologically active and has an authentic N-terminus, relatively free from endotoxins that results in minimization of adverse effects². Secretion also facilitates proper folding of proteins specially those requiring disulfide bridge formation, as it passes through a more favorable redox potential in the periplasmic space⁵².

Microbial sources of L-asparaginase

L-asparaginase is broadly distributed among the plants, animals and microorganisms. The most economical and the most commonly used microorganisms to produce L-asparaginase are *Aerobacter*, *Pseudomonas*, *Xanthomonas*, *Photobacterium*⁷⁰, *Proteus*⁹⁵, *Serratia*⁹, *Serratia marcescens*¹⁹, *Vibrio*⁴², *Aspergillus*⁸³, *Staphylococci*, *Aspergillus*, *Saccharomyces*¹⁰⁰, *Erwinia*⁵⁰, *Bacillus cereus* MNTG-7⁹¹, *Pectobacterium carotovorum* MTCC-1428⁵¹, *Bacillus*⁶² and *Bacillus subtilis* strain hswx88⁷¹. However the purified enzyme from *E. coli*, *Erwinia* sp. and *Serratia marcescens* has been used as anti-tumor and anti-leukemia agent.

Medium composition effecting L-asparaginase production

L-asparaginase producing microorganisms either produce this enzyme constitutively or after induction. The physicochemical conditions for L-asparaginase production vary with the microorganism.

Effect of Carbon source on L-asparaginase production

The synthesis of L-asparaginase in *E. coli* -W and *E. coli* K-12 was almost completely suppressed if glucose was added at a concentration of 0.5 % to the growth medium. This was because glucose caused catabolite repression and catabolite inhibition of the components involved in lactate transport²⁹ and lactate stimulated L-asparaginase synthesis.

Regulation mechanism of production of Staphylococcal L-asparaginase showed that carbon sources such as sucrose, maltose, galactose, lactose, mannitol and mannose inhibited L-asparaginase enzyme production⁷⁸.

Nocardia asteroides, an aerobic actinomycete, was grown in three different media, namely sabourand dextrose broth (SD), tryptic soy broth and synthetic medium, as a shake culture at 37°C for six days. The SD broth yielded maximum growth and showed maximum L-asparaginase production³³. L-asparaginase is an inducible enzyme and is generally induced in the presence of glucose. 0.2 % glucose is used as the carbon source³² which is proved to be a better isolation

method for the microbial cultures. The effect of glucose on optimum enzyme production has been reported by many workers^{29,51}. Glucose was also regarded as a repressor for L-asparaginase production in bacteria^{7,61}.

According to literature maximum L-asparaginase production was observed with maltose (0.5 %), glucose (0.2 %), glucose (0.38 %) in *Streptomyces gulbargensis*, *Pectobacterium carotovorum* MTCC 1428⁵¹, *Serratia marcescens* SK-07 respectively⁵.

Tapioca starch was the best carbon source with positive coefficient (6.390), where as fructose, mannitol, maltose and sucrose showed larger positive effects on the yields and the other carbon sources (Dextrose, Lactose, Dextrin white, Potato Starch, Starch soluble, Starch maize, Pharma starch, Xylose, Galactose, & Cellulose) were insignificant for L-asparaginase production in *Bacillus cereus* MNTG-7⁹¹.

Effect of Nitrogen source on L-asparaginase production

Organic acids and amino acids such as L-leucine and L-methionine were found to enhance production of L-asparaginase in *E. coli*⁶⁴. High L-asparaginase activity has been observed in bacterial cultures growing in ample nitrogen⁶⁸. In *Lupin arboreus*, plant parts such as leaves, root-tips, flower buds and developing seeds have been found to be sources of L-asparaginase¹⁵. L-asparaginase-I is constitutive and L-asparaginase-II is secreted in response to nitrogen starvation²¹. High L-asparaginase activity has been observed in bacterial cultures growing in ample nitrogen⁶⁷.

L-proline, Urea & L-asparagine⁷, were found as significant and best nitrogen sources for the production of L-asparaginase by *Aspergillus terreus* MTCC 1782. Gelatin is the best nitrogen source having positive coefficient of 3.50 in comparison with Soyabean meal, Tryptone, gelatin, Yeast extract, Soya peptone, Yeast nitrogen base, Casein, Meat extract, Peptone, Casaminoacids, Malt extract, Beef extract, Urea & Albumin for L-asparaginase production in *Bacillus cereus* MNTG-7⁹⁰. Among the amino acids (D-Alanine, L-Cystine, L-Alanine, L-Lysine, D-Arginine, L-Asparagine, L-arginine, L-Histidine, L-Glutamic

acid & L-Tryptophan), L-asparagine has the highest contribution (26.2 %) with positive coefficient of 4.75 for production of L-asparaginase in *Bacillus cereus* MNTG-7⁹¹.

C. glutamicum, produced L-asparaginase aerobically (pH 7.3) using casein and soya peptones as main nutrients⁵⁸. The *Bacillus* sp, isolated from an intertidal marine alga, *Sargassum* sp, produces constitutive L-asparaginase in the cultivation media (pH 8.0) at 28°C using peptone as the main nutrient⁵⁹.

The maximum amount of L-asparaginase produced from the optimized carbon and nitrogen medium containing Asparagine (5.5g/l) has been reported⁹⁴. The enzyme yielding capacity of *P. carotovorum* MTCC 1428 & *Bacillus* sp. BCCS 034 were found to be 14.2 IU/ml and 1.64 IU/ml in the supernatant^{22,51}.

In comparison to control with no carbon source at 37°C, lactose showed the maximum activity (16-fold) followed by monosodium glutamate (12-fold) by employing *E. carotovora*⁵³. Out of different nitrogenous substances added to the fermentation medium, cornsteep liquor showed 14-fold higher activity followed by tryptone (13-fold) and yeast extract (11-fold).

Intracellularly expressed L-asparaginase was also detected from *Enterobacter cloacae*⁶². Gram negative bacteria like *E. coli*¹⁰² and *E. cloacae*⁶³ utilized L-asparagine as the sole source of carbon and nitrogen. 0.1 % Maltose, Saccharose, Fructose and Galactose showed better enzyme production⁶³.

For the production of L-asparaginase by *Enterobacter aerogenes*, the most suitable C and N sources were sodium citrate and di-ammonium hydrogen phosphate, respectively⁶¹. Nitrogen catabolite repression on enzyme formation was absent in this bacteria but glucose was a repressor of this biosynthesis.

A pH of 7.9, casein hydrolysate (3.11 %) and corn-steep liquor (3.68 %) were the most significant factors for improving the enzyme production process by *Pseudomonas*⁸⁹.

Effect of fermentation process parameters

For *Staphylococcus* sp.-6A, incubation temperature, inoculum level and medium pH, among all fermentation factors, were the major

influential parameters at the individual level, and contributed to more than 60 % of total L-asparaginase production ⁷².

Optimization of temperature

The optimum temperatures for the production of enzyme by different Bacterial species have been reported as, 37°C for *Pseudomonas aeruginosa* 50071 ⁶ and *Staphylococcus* sp.- 6A ⁷¹, 40°C for *Streptomyces Gulbargensis* ³ & 30°C for *Bacillus brevis* ⁶¹. An organism identified as *Enterobacter cloacae* produced L-asparaginase (intracellularly which was resistant to a temperature range of 39-42°C and a good yield was obtained utilizing L-Fructose, D-Galactose, Saccharose or Maltose ⁶³.

Optimization of pH

The initial pH of the medium plays a vital role in the production of L-asparaginase. The best enzyme production in so far reported strains was at neutral pH. While media with slightly acidic pH have been reported for L-asparaginase production by bacteria such as 7.5 for *Staphylococcus* sp.- 6A ⁷¹, pH 6.5 for *Pectobacterium cartovorum* 1428 ⁵¹ and *Serratia marcescens* ¹. Alkaline media have been reported for the production of L-asparaginase such as pH 8.5 for *Streptomyces gulbargensis* ³. Production of L-asparaginase from a new *Erzoinia* sp. has been reported at optimum pH of 9.2 and the Km for L-asparagine was 2.8 mM ⁸. This *Erzoinia* sp. L-asparaginase is thermostable and followed linear kinetics, even at 77°C.

Role of aeration, agitation and dissolve oxygen level

Aeration of the fermentation medium is necessary for the growth of *Serratia marcescens*, but not for the production of asparaginase ³⁶. Enhanced biosynthesis of asparaginase by *E. coli* K-12 with anaerobic growth conditions has been reported ¹³. *Vitreoscilla* hemoglobin in *Erwinia aerogenes* and *Pseudomonas aeruginosa* respond differently to catabolic and oxygen repression for L-asparaginase production ³⁰.

During the cultivation in a fermenter the dissolved oxygen level was the limiting factor for L-asparaginase production ⁶¹.

Maximum L-asparaginase production of 29.89 U/mg was achieved in a batch bioreactor with 40 % Dissolve Oxygen level by employing *Serratia marcescens* SK-07 ¹.

Optimization of size of inoculum

The size of inoculum is also reported as one of the influencing factor for L-asparaginase production. 2 ml of inoculum having 0.8 absorbance of culture at 480 nm is the optimized inoculum for L-asparaginase production by *Staphylococcus* sp. - 6A ⁷².

Optimization of incubation period

The incubation period required for maximum production of the enzyme depends not only on the bacterium but also on the cultural conditions. The peak cell population and maximum L-asparaginase production by *Serratia marcescens* occurred simultaneously at 39 hr ³⁶. Maximum intracellular L-asparaginase production has been reported by *Pectobacterium carotovorum* ⁵ and *Bacillus brevis* ⁶¹ after 36 & 24 hours of incubation respectively.

Methods for purification of L-asparaginase

The major proposed application of L-asparaginase is as an injectible drug for the treatment of tumour or lymphoblastic leukemia in human beings. The sensitivity of application demands high degree of purity of this enzyme. L-asparaginase from *Mycobacterium phlei* was purified by fractionation with ammonium sulphate, absorption of contaminating proteins on calcium phosphate gel and chromatography on Sephadex G-150 and DEAE cellulose. The apparent Km for L-asparagine was 0.7 mM and the energy of activation was 9800 cal/mol ⁶⁷. Keiselguhr composite and CM sepharose has been used for large-scale production of asparaginase from *Erwinia chlysanthenzi* ³¹.

Extracellular L-asparaginase from *Candida utilis* was partially purified by acetone and by column chromatography on DEAE, Sephadex A-50 and Sephadex G-200. Optimum pH was 6 and the enzyme was stable for 10 minute at 50°C. Metal ions, SH inhibitor and chelating agents did not show any inhibition or activation of the enzyme ⁸².

Crude extracts of *Thermoactinomyces vulgaris* 13MES⁶⁰ were prepared after filtration of cultures and grinding the cells with sand, alumina or glass beads, by rapid freezing and thawing, by rapid mixing and also by exposure to ultrasonic waves. KSCN, NaClO₄ and Triton X-100 have been used for the solubilization of enzyme purified from *T. pyrilannis*⁹⁶.

Most of the microbial L-asparaginase is intracellular in nature except few, which are secreted outside the cells^{46,59}. In case of extracellular L-asparaginase from *C. utilis*, the enzyme was extracted from the cell precipitate or cell culture broth by the treatment of 2-mercaptoethanol, dithiothreitol or cysteine as a reducing agent⁴⁶. L-asparaginase from *Pseudomonas stutzeri*, after initial ammonium sulphate fractionation, was purified by consecutive column chromatography on sephadex G-200, calcium hydroxyapatite and DEAE sephadex A-50⁵⁴.

Asparagine catabolism in Bryophytes has been studied and purification and characterization of two forms of L-asparaginase, L-asparaginase-I and L-asparaginase-II, obtained from *Sphagnum fallax* was carried out by anion-exchange chromatography³⁵. They observed that the pH optimum of the enzyme was 8.2 and its molecular weight was 126,000. L-asparaginase from *Thermos thermophilus* has a dual L-asparaginase/kinase activity. It was purified and its apparent molecular mass by SDS-PAGE was found to be 33 kDa⁷³.

L-asparaginase was typically extracted by incubating the cells at 50°C for 4 hrs in extraction solution containing 2-mercaptoethanol in potassium phosphate buffer. *E. coli* cell permeabilization was also carried out with the help of K₂HPO₄ and triton X-100 and the release of L-asparaginase was over 70 %¹⁰⁸.

Molecular weight and properties of microbial L-asparaginase

L-asparaginase produced by *Streptomyces Gulbargensis*³, *Pseudomonas stutzeri* MB-405⁵⁴, *Sphagnum fallax*³⁵, *Thermos thermophilus*⁷² and *Erwinia carotovora*¹⁰³ have molecular weight of 82.12, 34, 126, 33 and 34.5 kDa respectively. SDS-PAGE analysis of purified recombinant L-asparaginase from *Escherichia*

*coli*⁴⁴ and *Erwinia Chrysanthemi* 3937⁵⁰ revealed single protein band migrating at 37 and 37.2 kDa protein respectively. This variation of molecular weight of L-asparaginase from different sources suggested that the molecular weight of the L-asparaginase is organism specific. The mol wt of *Corynebacterium glutamicum* L-asparaginase determined by gel filtration was 81,000 Da⁵⁷ and the apparent Km of L-asparaginase for L-asparagine was 2.5 mM.

Comparative experimental evaluation of immuno-depressive and toxic effects of L-asparaginase from *E. coli* and from *Erwinia carotovora* showed that L-asparaginase from *E. coli* is more immuno-depressive and immuno toxic than that from *E. carotovora*¹². Sulphydryl groups (-SH gps) of L-asparaginase from *P. fluorescens* were reported to be essential for enzyme activity⁸⁸. *E. coli* L-asparaginase has been shown to inhibit the growth of cultured pancreatic cells¹⁰³. Optimum pH of the *Rhodotorula rubra*, L-asparaginase enzyme was 7 and it was activated by Mg²⁺ and inhibited by Fe²⁺ and Pb²⁺²⁵. L-asparaginase of *Aspergillus nidulans* showed the clearest evidence of O₂ repression under N₂ metabolite derepressed conditions⁸⁵. Four forms of L-asparaginase were isolated from *Tetrahymena pyriformis*⁹⁹.

Mostly L-asparaginases are intracellular and the pH and temperature optima for L-asparaginase production are the same as that for the growth of the enzyme-producing organism⁵⁸. Presence of metal ions does not affect L-asparaginase production indicating that it is not a metalloprotein or does not require cofactors. Presence of chelating agents such as EDTA and compounds having thiol protecting groups such as glutathione, dithiothreitol, 2-mercaptoethanol etc. markedly enhance the enzyme activity⁷⁵.

L-asparaginase from *Tetrahymena pyriformis* was found in microsomal membranes. The enzyme exhibited an intrinsic phosphorylation activity with a Km value of 0.5 mM⁹⁹. The pH optima of purified *Staphylococcal* L-asparaginase were found to be between 8.6 and 8.8 while the temperature optima were 30-32°C.⁸⁷

L-asparaginase from *Erwinia carotovora* showed maximum activity at pH 8.0 and at 50°C temperature. The Km value of purified enzyme

was 1.8×10^{-5} M. Purified enzyme showed significant antitumour activity on experimental animal models⁵³.

Two forms of L-asparaginase, L-asparaginase-I and L-asparaginase-II, were extracted and purified from *Thermos thermophilus*⁹⁸. The two forms acted optimally at pH 8.6. The L-asparaginase activity from *Bacillus* sp. was found to be optimum at pH 8.0⁵⁹ and temperature at 37°C. The enzyme activity decreased sharply above 40°C and the enzyme was inactivated at 50°C and exhibited a half-life period of about 1 hr. Km value of L-asparaginase from *Bacillus* sp was found to be 2.4×10^{-4} M. An extracellular asparaginase from *Rhodospiridium toruloides* has been reported to be a homodimer having pH optima of 6.35 and temperature optima of 37°C⁷⁶.

Biochemical aspects of L-asparaginase

The medical utilization of L-asparaginase from the reported sources suffer the limitations of eliciting immunological responses leading to hypersensitivity in the long-term usage¹⁰⁰, allergic reactions⁷⁷, anaphylaxis and instance of spontaneous resistance of the tumor cells^{20,84}. Biochemical aspects play a vital role in enzyme production studies. Erwinia asparaginase is considered to be less toxic compared to *E. coli* asparaginase and hence is employed in the events of allergic reactions inspite of having a shorter half life than *E. coli* asparaginase. This enzyme was characterized by X-ray scattering (saxs) pattern of homo tetrameric asparaginase-II from *E. coli* was measured in solution in conditions resembling those in which its crystal form was obtained and compared.

L-asparaginase assay method

Many attempts have been made by researchers for the assay of L-asparaginase and for monitoring its activity. L-asparaginase was assayed based on the production of ammonia during hydrolysis of L-asparagine degraded by glutamate dehydrogenase consequently with the oxidation of β -NADH³². Enzymatic assay of L-asparaginase is also done by Nesslerization method. The reaction is monitored by measuring the amount of ammonia released during reaction. The ammonia released is complexed with Nessler's reagent and

the resultant reddish brown solution's optical absorbance is measured at 436 nm using UV-Visible spectrophotometer. Using ammonium standard curve, the enzyme activity will be calculated.

Automated enzymatic analysis with potentiometer ammonia detection by on-line gas analyzer for has been implemented²⁷ where an ammonia electrode was incorporated in conjunction with a pre-dialysis unit. A multi-analyte miniature conductance biosensor using enzymes such as urease and L-asparaginase and a three enzyme system consisting of urease, creatinase and creatininase for determining urea, L-asparagine and creatinine, respectively is also applicable¹⁸. An enzymatic method has been developed for the kinetic measurement of L-asparaginase activity and L-asparagine with an ammonia gas-sensing electrode. This method is based upon the deamination of L-asparagine by L-asparaginase from *E. coli* resulting in the formation of ammonia⁹². Garlic tissue electrode has been used for determination of L-asparagine⁴⁷. Garlic tissue cells were employed for conversion of L-asparagine into ammonia. An ammonium gas electrode (ISE) was used as the detector. The combination of L-asparaginase in garlic tissue cells and gas electrode responds linearly to L-asparagine concentration. L-asparaginase from *Erwinia clynsanthemi* was assayed fluorometrically by incubating it with beta L-aspartic acid and measuring the release of 7-amino-4-methylcoumarin¹⁰⁶. A thermostable recombinant asparaginase from *Archaeoglobus fidgeus* was cloned and expressed in *E. coli* as a fusion protein. It was later purified by an immobilized metal ion affinity chromatography method and its activity was determined by monitoring the change in the ammonia concentration in solution. The enzyme was immobilized and used with an ammonium selective electrode (ISE) to develop a biosensor for L-asparaginase¹⁰¹.

Side effects

Besides minor side effects such as an allergic reaction and vomiting, L-asparaginase therapy of Acute Lymphoblastic Leukemia has some serious side effects. Onset of venous thrombosis in children undergoing histopathologic disease due

to Acute Lymphoblastic Leukemia therapy has been reported⁸¹. Neutropenic enterocolitis has been observed as an unusual acute complication of neutropenia, associated with leukaemia and lymphoma⁷⁴. Hypersensitivity reactions to chemotherapeutic anti-neoplastic agents such as L-asparaginase⁷⁷ have been reported. Tubular and glomerular dysfunction due to Acute Lymphoblastic Leukemia chemotherapy have been observed³⁹. Urethral obstruction was observed due to L-asparaginase induced pancreatitis during treatment of Acute Lymphoblastic Leukemia¹⁶. Myocardial ischemia has been observed in a patient with acute lymphoblastic leukaemia⁸⁴ due to L-asparaginase therapy.

An outburst of acute pancreatitis, called “drug induced pancreatitis” (DIP), has been reported by Trivedi, C.D., Pitchumoni, C.,⁹⁷. A cerebral thrombotic complication in adolescent leukaemia patients⁴⁰ has been attributed to L-asparaginase treatment. Acute hepatic dysfunction⁴ and immunodeficiency in children with ALL¹⁰ have been other major side effects. Ocular complications arise due to L-asparaginase treatment²⁶, but symptoms ease out by discontinuing treatment and carrying on treatment with heparin. Growth hormone deficiency in children receiving chemotherapy for acute lymphoblastic leukaemia has been reported³⁴. Growth impairment after cranial radiation (CR) can result in diminished adult height. L-asparaginase treatment induced severe, acquired, and transient type I deficiency of antithrombin (and 1-antitrypsin) with intracellular accumulation of the nascent molecule, increasing the risk of thrombosis³⁷. A study on the consequences of L-asparaginase on antithrombin levels in plasma from acute lymphoblastic leukemia patients, HepG2 cells, and plasma and livers from mice treated with this drug has been carried out by Hernandez-Espinosa, *et.al.*,³⁷. They reported that asparaginase treatment induced severe, acquired, and transient type I deficiency of antithrombin (and 1-antitrypsin) with intracellular accumulation of the nascent molecule, increasing the risk of thrombosis.

L-asparaginase an enzyme of medical interest and scope of research

L-asparaginase has been a major research

subject for many researchers worldwide. The FDA has approved L-asparaginase for the effective treatment of acute lymphoblastic leukemia and lymphosarcoma. Its therapeutic potential is now well established, as it has remarkably induced remission in most of the patients suffering with ALL. The antileukemic action of the preparation made in the USSR was superior to the preparation (leumase) made in Japan. L-asparaginase made in USSR and Germany was recommended for clinical use.

Preventase (DSM) and Acrylaway (Novozyme) produced from *Aspergillus niger* and *A. oryzae* respectively are commercially available L-asparaginase currently used in food industry⁴⁸ for the production of acrylamide (a potent carcinogen and a neurotoxic compound) free starchy fry food⁶⁹.

The thermozymes from thermophilic organisms thrive under high temperature environments (45 to 100°C) are ideal microbiological niche to explore L-asparaginase production and preferred due to their guaranteed properties of stability in adverse conditions at which different industrial processes operate²¹ and to combat adverse effects of the existing enzyme. Imanaka and his associates reported that the thermostability of protein will be made possible through a single amino acid substitution⁴¹. More research is required for the production of cost effective, eco-friendly, thermostable and a potent L-asparaginase with new antigenic properties. Thermozymes extracted from extreme environment might produce a serologically different L-asparaginase with novel immunological properties to that of proteins extracted at normal conditions.

Conclusion

The present review highlighted the key issues related to the use of L-asparaginase by researchers across the globe for patient benefits and effective control for the treatment of various types of malignancies, source, associated hypersensitivity and side effects to be addressed, properties, statistical optimization studies for bioprocess development of a novel, economically viable, safe, stable and potent extracellular enzyme with higher yield.

References

1. **Agarwal, A., Kumar, S., Veeranki, V.D. (2011).** Effect of chemical and physical parameters on the production of L-asparaginase from a newly isolated *Serratia marcescens* SK-07. *Letters in Applied Microbiology*. 52: 307-13.
2. **Amardeep, K., Yogender, P., Bhairab, N.S., Mukherjee, K.J. (2004).** Extracellular expression and single step purification of recombinant *Escherichia coli* L-asparaginase II. *Protein expression and purification*. 38: 29-36.
3. **Amena, S., Vishalakshi, N., Prabhakar, M., Dayanand, A., Lingappa, K. (2010).** Production, purification and characterization of L-asparaginase From *Streptomyces Gulbargensis*, *Brazilian Journal of Microbiology*. 41: 173-178.
4. **Aoki, C.A., Bowlus, C.L., Rossaro, L. (2005).** An adult case of acute lymphoblastic leukemia presenting as hepatic dysfunction. *Dig. Liver Dis*. 37(3): 206-210.
5. **Arrivukkarasan, S., Muthusivaramapandian, M., Aravindan, R., Viruthagiri, T. (2010).** Effect of Medium Composition and Kinetic Studies on Extracellular and Intracellular Production of L-asparaginase from *Pectobacterium carotovorum*. *Food Science and Technology International*. 16(2): 0115-11.
6. **Ashraf, A.E.B., Sarhan, M., Mansour, J. (2004).** Production, Isolation, and Purification of L-Asparaginase from *Pseudomonas Aeruginosa* 50071 Using Solid-state Fermentation. *Journal of Biochemistry and Molecular Biology*. 37(4), 387-393.
7. **Baskar, G., Renganathan, S. (2009).** Statistical screening of process variables for the production of L-asparaginase from cornflour by *Aspergillus terreus* MTCC 1782 in submerged fermentation. *Indian Journal of Science and Technology*. 2(5): 45-48.
8. **Borkotaky, B., Bezbaruah, R.L. (2002).** Production and properties of asparaginase from a new *Erwinia* sp. *Folia Microbiologica*. 47(5): 473-476.
9. **Boyd, J.W., Phillips, A.W. (1971).** Purification and Properties of L-Asparaginase from *Serratia marcescens*. *Journal of Bacteriology*. 106(2), 578-587.
10. **Brodman, D.H., Rosenthal, D.W., Redner, A., Lanzkowsky, P., Bonagura, V.R. (2005).** Immunodeficiency in children with acute lymphoblastic leukemia after completion of modern aggressive chemotherapeutic regimens. *J. Pediatr*. 146 (5): 654-661.
11. **Broome, J.D. (1961).** Evidence that the L-asparaginase activity of guinea pig serum is responsible for its antilymphoma effects. *Nature*. 191: 1114-1115.
12. **Cavana, M., Celle, G., Doderio, M., Picciotto, A., Pannacciulli, I., Brambilla, G. (1997).** Comparative experimental evaluation of immune depressive and toxic effects of L-asparaginase N5C-109229 from *Escherichia coli* and from *Erwinia carotovora*. *Cancer Treatment Reports*. 60(3): 255-257.
13. **Cedar, H., Schwartz, J.H. (1968).** Production of L-asparaginase II by *Escherichia coli*. *Journal of Bacteriology*. 96: 2043-48.
14. **Chakrabarti, R. (1997).** L-asparaginase perspectives on the mechanisms of action and resistance. *Int. J. Pediatr. Hematol Oncol.*, 4: 597-611.
15. **Chang, K.S., Farnden, K.J.F. (1981).** Purification and properties of Asparaginase EC-3.5.1.1 from *Lupinus arboreus* and *Lupinus angustifolius*. *Archives of Biochemistry and Biophysics*. 208(1): 49-58.
16. **Chen, C.H., Lu, M.Y., Lin, K.H., Lin, D.T., Peng, S.F., Jou, S.T. (2004).** Ureteral obstruction caused by L-asparaginase-induced pancreatitis in a child with acute lymphoblastic leukemia. *J. Formos Med. Assoc.*, 103(5): 380-384.
17. **Clementi, A. (1922).** L-asparaginase desamidation enzymatique de L-asparagine chez les differences especes animales et L-asparaginase signification physiologique de sa presence dans l'organisma. *Arch. Int. Physiol*. 19: 369-376.

18. **Cullen, D.C., Sethi, R.S., Lowe, C.R. (1990).** Multi-analyte miniature conductance biosensor. *Analytica Chimica Acta.* 231 (1): 33-40.
19. **Dejong, P.J. (1972).** L-asparaginase production by *Streptomyces griseus*. *Applied Environmental Microbiology.* 23: 1163-1164.
20. **Demirjian, D.C., Moris, V.F., Cassidy, C.S. (2001).** Enzymes from extremophiles. *Current Opinion in Chemical Biology.* 5(2): 144-51.
21. **Dunlop, P.C., Meyer, G.M., Ban, D., Roon, R.I. (1978).** Characterisation of two forms of asparaginase in *Saccharomyces cerevisiae*. *Journal of Biological Chemistry.* 253 (4): 1297-1304.
22. **Ebrahiminezhad, A., Rasoul-Amini, S., Ghasemi Y. (2011).** L-asparaginase production by moderate halophilic bacteria isolated from Maharloo salt lake. *Indian Journal of Microbiology.* 51(3): 307-11.
23. **El-Sayed, M., El-Sayed, S.T., Shousha, W.G., Shehata, N.A., Hanafy, S.S. (2011).** Purification, Characterization and Antitumor Activity of L-asparaginase from Chicken liver. *Journal of American Science.* 7(1): 439-449.
24. **Ettinger, L.J., Ettinger, A.G., Avramis, V.I., Gaynon, P.S. (1997).** Acute lymphoblastic leukemia: a guide to asparaginase and pegaspargase therapy. *Bio. Drugs.* 7: 30-39.
25. **Foda, M.S., Zedan, H.H., Hashem, S.A.E.M. (1980).** Characterization of a novel L-asparaginase produced by *Rhodotorula rubra*. *Revista Latinoamericana de Microbiologia* 22(2): 87-96.
26. **Foroozan, R. (2005).** Ocular complications of sigmoid sinus thrombosis from L-asparaginase. *J Pediatr Ophthalmol Strabismus.* 42 (2): 117-119.
27. **Fratlicelli, Y.M., Meyerhoff, M.E. (1983).** Online gas analyser for automated enzymatic analysis with potentiometric ammonia detection. *Analytical Chemistry.* 55(2): 359-364.
28. **Gallagher, M.P. (1989).** L-Asparaginase a drug for treatment of acute lymphoblastic leukemia. *Essays Biochemistry.* 24: 1-40.
29. **Garaev, M.M., Golub, E.I. (1977).** Mechanism of the effect of glucose on L-asparaginase synthesis by *Escherichia coli* bacteria. *Mikrobiologiya.* 46(3): 433-439.
30. **Geckil, H., Gencer, S., Uckun, M. (2004).** *Vitreoscilla* hemoglobin expressing *Enterobacter aerogenes* and *Pseudomonas aeruginosa* respond differently to carbon catabolite repression for production of L-asparaginase an enzyme used in cancer therapy. *Enzyme and Microbial Technology.* 35(3): 182-189.
31. **Goward, C.R., Stevens, G.B., Collins, I.J., Wilkinson, I.R., Scawen, M.D. (1989).** Use of macrosorb keiselguhr composite and CM-sepharose fast flow for the large-scale purification of L-asparaginase from *Erwinia chrysanthemi*. *Enzyme and Microbial Technology.* 11(12): 810-814.
32. **Gulati, R., Saxena, R.K., Gupta, R. (1997).** A rapid plate assay for screening L-asparaginase producing micro-organisms. *Letter of Applied Microbiology.* 24: 23-26.
33. **Gunasekaran, S., McDonald, L., Manavathu, M., Manavathu, E., Gunasekaran, M. (1995).** Effect of culture media on growth and L-asparaginase production in *Nocardia asteroides*. *Bio-medical Letters.* 52(207): 197-201.
34. **Haddy, T.B., Mosher, R.B., Nunez, S.B., Beaman, G.H. (2006).** Growth hormone deficiency after chemotherapy for acute lymphoblastic leukaemia in children who have not received cranial radiation. *Pediatric Blood and Cancer.* 46(2): 258-261.
35. **Heeshen, V., Matlok, J., Schrader, S., Rudolph, H. (1996).** Asparagine catabolism in bryophytes: Purification and characterization of two L-asparaginase isoforms from *Sphagnum fallax*. *Physiologia Plantarum.* 97(2): 402-410.
36. **Heinemann, B., Howard, A.J. (1969).** Production of tumor-inhibitory L-asparaginase by submerged growth of *Serratia marscescens*. *Applied Microbiology.* 18: 550-554.
37. **Hernandez, E.D., Minano, A., Martinez, C., Perez, C.E., Heras, I., Fuster, J.L., Vicente, F.V., Corral, J. (2006).** L-Asparaginase-Induced Antithrombin Type I Deficiency. *American*

- Journal of Pathology. 169: 142-153.
38. <http://www.who.int/medicines/publications/essentialmedicines/en/index.html>,(2014). "WHO Model List of Essential Medicines" World Health Organization. October 2013. Retrieved. 22 April
 39. **Ikarashi, Y., Kakihara, T., Imai, C., Tanaka, A., Watanbe, A., Uchiyama, M. (2004).** Glomerular dysfunction, independent of tubular dysfunction, induced by antineoplastic chemotherapy in children. *Pediatr Int.* 46(5): 570-575.
 40. **Imamura, T., Morimoto, A., Kato, R., Izumi, M., Murakami, A., Matuo, S., Kivosawa, N., Kano, G., Yoshioka, H., Sugimoto, T., Imashuku, S. (2005).** Cerebral thrombotic complications in adolescent leukemia/lymphoma patients treated with L-asparaginase containing chemotherapy. *Leuk Lymphoma.* 46(5): 729-735.
 41. **Imanaka, T., Shibazaki, M., Takagi, M. (1986).** A new way of enhancing the thermostability of proteases. *Nature.* 324: 695-97.
 42. **Kafkewitz, D., Goodman, D. (1974).** L-asparaginase production by the rumen anaerobe *Vibrio succinogenes*. *Applied Environmental Microbiology.* 27: 206-209.
 43. **Keating, M.J., Holmes, R., Lerner, S.H. (1993).** Lasparaginase and PEG asparaginase past, present and future. *Leuk. Lymphoma.* 10: 153-157.
 44. **Khushoo, A., Pal, Y., Singh, B.N., Mukherjee, K.J. (2004).** Expression and single step purification of recombinant *Escherichia coli* L-asparaginase II. *Protein Expression and Purification.* 38(1): 29-36.
 45. **Kidd, J.G. (1953).** Regression of transplanted lymphomas induced in vivo by means of normal Guinea pig serum. *J. Exp. Med.* 98: 583-591.
 46. **Kil, J.O. (1995).** Extraction of extracellular L-asparaginase from *Candida utilis*. *Biosci Biotechnol Biochem.* 59: 749-750.
 47. **Kim, S.J., Kim, G.M., Bae, Y.J., Lee, E.Y., Hur, M.H., Ahn, M.K. (1995).** Determination of L-asparagine using a garlic tissue electrode. *Yakhak Hoef.* 39(2): 113-117.
 48. **Kodchakorn, L., Saisamorn, L., Sutheera, T., Pairote, W., Uraporn, S. (2012).** L-asparaginase production by *Bipolaris* sp. BR438 isolated from brown rice in Thailand. *Chiang Mai. Journal of Science.* 37(1): 160-164.
 49. **Kolganova, T.V., Dzharatat, T., Ermolaev, A.V., Osipova, I.G., Vasileva, E.A., Dalin, M.V., Doyle, R.J. (2002).** Complex effects of pulsed infrared laser and asparaginase on *Escherichia coli* Strains Isolated from Patients with urinary Diseases. Translated from *Byulleten 'Eksperimental' noi Biologii i Meditsiny.* 133(6): 681-683.
 50. **Kotzia, A.G., Labrou, E.N. (2007).** L-asparaginase from *Erwinia Chrysanthemi* 3937: Cloning, expression and characterization. *Journal of Biotechnology.* 127: 657-69.
 51. **Kumar, S., Dasu, V.V., Pakshirajan, K. (2010).** Localization and production of novel L-asparaginase from *Pectobacterium carotovorum* MTCC 1428. *Process Biochemistry.* 45: 223-229.
 52. **Makrides, S.C. (1996).** Strategies for achieving high-level expression of genes in *Escherichia coli*. *Microbiol Rev.* 60: 512-538.
 53. **Maladkar, N.K. (1993).** Fermentative production and isolation of L-asparaginase from *Erwinia carotovora*, EC113. *Hindustan Antibiotic Bull.* 77-86.
 54. **Manna, S. (1995).** Purification characterization and antitumour activity of L-asparaginase isolated from *Pseudomonas stutzeri* MB-405. *Curr. Microbiol.* 30: 291-198.
 55. **Frost and Sullivan. (2010).** Market I I E, Research and Markets, Dublin.
 56. **Marrs, B., Delagrave, S., Murphy, D. (1999).** Novel approaches for discovering industrial enzymes. *Curr Opin Microbiol.* 2: 241-245.
 57. **Martin, J.F. (1989).** Molecular genetics of amino acid producing *Corynebacteria*. *Symp. sac. Gen. Microbiol.* 44: 25-59.

58. **Mesas, J.M., Gill, J.A., Martin, J.F. (1990).** Characterization and partial purification of L-asparaginase from *Corynebacterium glutamicum*. *J. Gen. Microbiol.* 136: 515-519.
59. **Mohapatra, B.R. (1995).** Characterization of L-asparaginase from *Bacillus* sp isolated from an intertidal marine alga (*Sargassum* sp). *Lett. Appl. Microbiol.* 21: 380-383.
60. **Mostafa, S.A., Ali, O.A. (1983).** L-asparaginase activity in cell free extracts of *Thermoactinomyces vulgaris* 13 M.E.S. *Zbl Microbiol.* 5: 397-404.
61. **Mukherjee, J., Majumdar, S., Scheper, T. (2000).** Studies on nutritional and oxygen requirements for production of L-asparaginase by *Enterobacter aerogenes*. *Applied Microbiology & Biotechnology.* 53: 180-84.
62. **Narta, U., Roy, S., Shamsher., Kanwar, S., Azmi, W. (2011).** Improved production of L-asparaginase by *Bacillus brevis* cultivated in the presence of oxygen-vectors. *Bioresource Technology.* 102: 2083-2085.
63. **Nawaz, M.S., Zhang., Cernigliola. (1998).** Isolation and characterization of *Enterobacter cloacae* capable of metabolizing L-asparagine. *Appl Microbiol Biochem.* 50: 568-572.
64. **Netrval, J. (1977).** Stimulation of L-asparaginase production in *Escherichia coli* by organic and amino acids. *Folia Microbiologica.* 22 (2): 106-116.
65. **Neuman, R.E., McCoy, T.A. (1956).** Dual requirement of Walker carcinoma 256 in vitro for L-asparagine and Glutamine. *Science.* 124: 124-131.
66. **Parameswaran, B., Piyush, P., Raghavendra, G., Nampootheri, K.M., Arvind, D., Kakali, D., Ashok, P. (2013).** Industrial Enzymes-Present status and future perspectives for India. *Journal of Scientific & Industrial Research.* 72: 271-286.
67. **Pastuszak, I., Szymona, M. (1976).** Purification and properties of L-asparaginase EC-3.5.1.1 from *Mycobacterium phial.* *Acta Biochimica Polonica.* 23(1): 37-44.
68. **Paul, J.H., Cooksey, K.E. (1981).** Regulation of L-asparaginase E.C.-5.1.1 in a *Chlamydomonas* species in response to ambient concentrations of combined nitrogen. *Journal of Bacteriology.* 147 (1): 9-12.
69. **Pedreschi, F., Kaack, K., Granby, K. (2008).** The effect of asparaginase on acrylamid formation in French fries. *Food Chemistry.* 109: 386-392.
70. **Peterson, R.E., Ciegler, A. (1969).** L-asparaginase production by various bacteria. *Applied Environmental Microbiology.* 17: 929-930.
71. **Pradhan, B., Dash, S.K., Sahoo, S., (2013),** Screening and characterization of extracellular L-asparaginase producing *Bacillus subtilis* strain *hswx88*, isolated from Taptapani hot spring of Odisha, India. *Asian Pac. J. Trop. Biomed.* 3(12): 936-941.
72. **Prakasham, R.S., Rao, C.S., Rao, R.S., Lakshmi, G.S., Sarma, P.N. (2007).** L-asparaginase production by isolated *Staphylococcus* sp. - 6A: design of experiment considering interaction effect for process parameter optimization. *Journal of Applied Microbiology.* 102: 1382-1391.
73. **Prista, A.A., Kyridio, D.A. (2001).** L-asparaginase of *thermotherophilus*: purification, properties and identification of essential amino acids for catalytic activity. *Mol. Cell. Biochem.* 216: 93-101.
74. **Radulovic, S., Golubovic, Z., Jovanovic, B., Pejanovic, J. (2004).** Surgery for neutropenic enterocolitis, a complication in acute lymphoblastic leukemia. *Srp. Arh. Celok. Lek.* 132(1): 119-121.
75. **Raha, S.K., Roy, S.K., Dey, S.K., Chakrabarty, S.L. (1990).** Purification and properties of an L-asparaginase from *Cylindrocarpum obtusisporum* MB- 10. *Biochem. Int.* 2: 987-1000.
76. **Ramaiah, N., Chandramohan, D. (1992).** Production of L-asparaginase by the marine luminous bacteria. *Indian Journal of Marine Sciences.* 21: 212-214.
77. **Rossi, F., Incorvaia, C., Mauro, M. (2004).** Hypersensitivity reactions to chemotherapeutic antineoplastic agents. *Recent Prog. Med.* 95(10): 476-481.

78. **Rozalska, M., Mikucki, J. (1992).** Staphylococcal L-asparaginase: Catabolic repression of synthesis. *Acta Microbiologica Polonica.* 41: 145-150.
79. **Sahoo S. (2008).** Bioprocess Development for Production of Industrially Important Enzyme by Fermentation Technique with Special Reference to Strain Improvement, Characterization and its Purification, Ph. D. Thesis. Utkal University, Vani Vihar, India.
80. **Sahoo, S. (2013).** Microbial Enzymes: Prospects and Challenges, ed. Rath C C, Microbiology Applications, 211-233, Har Krishan Bhalla & Sons, Dehradun, India.
81. **Sahoo, S., Hart, J. (2003).** Histopathological features of L-asparaginase induced liver disease. *Semin Liver Dis.* 23 (3): 295-299.
82. **Sakamoto, T., Araki, C., Beppu, T., Arima, K. (1977).** Partial purification and some properties of extracellular Asparaginase from *Candida utilis*. *Agricultural and Biological Chemistry.* 41(8), 1359-1364.
83. **Sarquis, M., Oliveira, E., Santos, A., Costa, G. (2004).** Production of L-asparaginase by filamentous fungi. *Mem. Inst. Oswaldo. Cruz.* 99: 489-492.
84. **Saviola, A., Luppi, M., Potenza, L., Morselli, M., Bresciani, P., Ferrari, A., Riva, G., Torelli, G. (2004).** Myocardial ischemia in a patient with acute lymphoblastic leukemia during L-asparaginase therapy. *Euri Haematol.* 72(1): 71-72.
85. **Schemer, G., Holcenberg, J.S. (1981).** Enzymes as drugs, edited by J S Holcenberg & J. Roberts. Wiley Inter Science, New York 455-473.
86. **Shaffer, P.M., Arst, H.N. J., Estberg, L., Fernando, L., Tran, L., Sitter, M. (1988).** An asparaginase of *Aspergillus nidulans* is subject to oxygen repression in addition to nitrogen metabolite repression. *Mol. Gen. Genet.* 212: 337-341.
87. **Sobis, M., Mickucki, J. (1991).** Staphylococcal L-asparaginase: Enzyme Kinetics. *Acta Microbiologica Polonica.* 40: 145-150.
88. **Sokolov, N.N., Nikolaev, A.Y. (1976).** Sulfhydryl groups of L-asparaginase from *Pseudomonas fluorescens* AG. *Biokhimiya.* 41(4): 727-731.
89. **Sonawane, A., Kloppner, U., Hovel, S., Volker, U., Rohm, K.H. (2003).** Identification of *Pseudomonas* proteins coordinately induced by acidic amino acids and their amides: a two-dimensional electrophoresis study. *Microbiology.* 149: 2909-2918.
90. **Soniyamby, A.R., Lalitha, S., Praveesh, B.V., Priyadarshini, V. (2011).** Isolation, Production and Anti-Tumor Activity of LA of *Penicillium* sp.. *International Journal of Microbial Research.* 2(1): 38-42.
91. **Sunitha, M., Ellaiah, P., Bhavani, D.R. (2010).** Screening and optimization of nutrients for Lasparaginase production by *Bacillus cereus* MNTG-7 in SmF by plackett-burmann design. *African Journal of Microbiology Research.* 4: 297-303.
92. **Tagami, S., Masuda, K. (1990).** An enzymatic method for the kinetic measurement of L-asparaginase activity and L-asparagine with an ammonia gas-sensing electrode. *Chemical and Pharmaceutical Bulletin.* 38(1): 153-155.
93. **Teodor, E., Litescu, S.C., Lazar, V., Somoghi, R. (2009).** Hydrogel-magnetic nanoparticles with immobilized L-asparaginase for biomedical applications. *J. Mater. Sci. Mater. Med.* 20: 1307-1314.
94. **Thenmozhi, C., Sankar, R., Karuppiyah, V., Sampathkumar, P. (2011).** L-asparaginase production by mangrove derived *Bacillus cereus* MAB5: optimization by response surface methodology. *Asian Pacific Journal of Tropical Medicine.* 486-91.
95. **Tosa, T., Sano, R., Yamamoto, K., Nakamura, M., Ando, K., Chibata, I. (1971).** L-asparaginase from *Proteus vulgaris*. *Applied Environmental Microbiology.* 387-392.
96. **Triantafyllou, D.J., Georgatsos, J.G., Kyriakidis, D.A. (1988).** Purification and properties of a membrane bound L-asparaginase of *Tetrahymena pyriformis*. *Molecular and Cellular Bio-*

- chemistry. 81(1): 43-51.
97. **Trivedi, C.D., Pitchumoni, C. (2005).** Drug induced pancreatitis: An update. *Journal of Clinical Gastroenterology*. 39(8): 709-716.
 98. **Tsavidaridis, I.K., Triantafillidou, D.C., Kyriakidis, D.A. (1994).** Two forms of L-asparaginase in *Thermus thermophilus*. *Biochemistry and Molecular Biology International*. 32(1): 67-77.
 99. **Tsirka, S.A.E., Kyriakidis, D.A. (1989).** A model for the regulation of the activity of L-asparaginase kinase enzyme of *Tetrahymena pyriformis*. *Biochemistry International*. 19(1): 9-18.
 100. **Verma, N., Kumar, K., Kaur, G., Anand, S. (2007).** L-asparaginase: a promising chemotherapeutic agent. *Crit. Rev. Biotechnol.* 27: 45-62.
 101. **Wang, J., Li, J., Bachas, L.G. (2002).** Biosensor for asparagine using a thermostable recombinant asparaginase from *Archeoglobus fulgidus*. *Anal. Chem.* 74(14): 3336-3341.
 102. **Wei, D.Z., Liu, H. (1998).** Promotion of L-asparaginase using n-dodecane. *Biotechnology Techniques*. 12(2): 129-131.
 103. **Wink, P.L., Bogdawa, H.M., Renard, G., Chies, J.M., Basso, L.A., Santos, D.S. (2010).** Comparison between Two *Erwinia carotovora* L-Asparaginase II Constructions: cloning, Heterologous Expression, Purification, and Kinetic Characterization. *J. Microbial. Biochem. Technol.* 2(1): 013-019.
 104. **Wu, M.C., Arimura, G.K., Yunis, A.A. (1978).** Mechanism of sensitivity of cultured pancreatic carcinoma to Asparaginase. *International Journal of Cancer*. 22(6): 728-733.
 105. **Yellin, T.Y., Wriston, J.C. (1966).** Antagonism of purified asparaginase from guinea pig serum towards lymphoma. *Science*. 151: 998-1004.
 106. **Ylikangas, P., Mononen, I.A. (2000).** fluorometric assay for L-asparaginase activity and monitoring of L-asparaginase therapy. *Analytical Biochemistry*. 280(1): 42-45.
 107. **Yunis, A.A., Arimures, G.K., Russin, D.J. (1997).** Human pancreatic carcinoma (MIA PaCa-2) in continues culture sensitivity to Asparaginase. *International Journal of Cancer*. 19: 218-235.
 108. **Zaho, F., Yu, J. (2001).** L-Asparaginase release from *Escherichia coli* cells with K₂HPO₄ and Triton X- 100. *Biotechnol Progr.* 17(3): 490-494.